Private Trust Co. NA Sells 417 Shares of Solventum Co. (NYSE:SOLV)

Private Trust Co. NA lowered its holdings in shares of Solventum Co. (NYSE:SOLV) by 13.3% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,723 shares of the company’s stock after selling 417 shares during the period. Private Trust Co. NA’s holdings in Solventum were worth $190,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Tokio Marine Asset Management Co. Ltd. boosted its position in shares of Solventum by 4.2% in the 3rd quarter. Tokio Marine Asset Management Co. Ltd. now owns 4,966 shares of the company’s stock worth $346,000 after purchasing an additional 200 shares in the last quarter. National Bank of Canada FI grew its stake in shares of Solventum by 4.0% in the second quarter. National Bank of Canada FI now owns 6,093 shares of the company’s stock worth $314,000 after acquiring an additional 236 shares during the last quarter. IVC Wealth Advisors LLC increased its holdings in shares of Solventum by 5.0% during the third quarter. IVC Wealth Advisors LLC now owns 6,649 shares of the company’s stock valued at $464,000 after acquiring an additional 318 shares in the last quarter. KKM Financial LLC raised its position in shares of Solventum by 7.9% in the 3rd quarter. KKM Financial LLC now owns 4,367 shares of the company’s stock worth $304,000 after purchasing an additional 319 shares during the last quarter. Finally, Copeland Capital Management LLC bought a new position in Solventum in the 3rd quarter worth about $26,000.

Solventum Price Performance

Solventum stock opened at $72.48 on Friday. Solventum Co. has a 52-week low of $47.16 and a 52-week high of $96.05. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.83 and a current ratio of 1.15. The business has a 50-day simple moving average of $70.52 and a two-hundred day simple moving average of $62.54.

Wall Street Analyst Weigh In

Several brokerages have issued reports on SOLV. Morgan Stanley lifted their target price on shares of Solventum from $60.00 to $73.00 and gave the stock an “equal weight” rating in a report on Monday, November 11th. BTIG Research started coverage on Solventum in a report on Thursday, September 5th. They issued a “neutral” rating for the company. The Goldman Sachs Group boosted their price target on Solventum from $48.00 to $54.00 and gave the stock a “sell” rating in a research note on Monday, August 12th. Stifel Nicolaus assumed coverage on Solventum in a research report on Tuesday, October 8th. They set a “buy” rating and a $82.00 price objective on the stock. Finally, Piper Sandler upped their target price on shares of Solventum from $71.00 to $75.00 and gave the company a “neutral” rating in a research note on Friday, November 8th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and one has given a buy rating to the company’s stock. Based on data from MarketBeat.com, Solventum presently has an average rating of “Hold” and a consensus target price of $68.00.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.